Karius: Funding, Investors & Team (Sep 2026)
Karius is a biotech company that specializes in providing genomic information on infectious diseases through a non-invasive liquid biopsy. Their Karius Test aids healthcare providers in quickly determining the most effective treatment options. With the ability to analyze a patient's microbial makeup from just one blood sample, Karius aims to reduce the impact of infectious diseases on global health. The company's laboratory is certified by CLIA and accredited by CAP to conduct advanced clinical testing.
Karius has raised $265M across 2 funding rounds on record, the most recent a Series C of $100M announced in May 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Karius Company Profile and Key Stats
Latest funding round on record: May 2024.
Karius Funding Rounds
Karius raised $165M in an undisclosed round announced in Feb 2020.
4.3 years later, a Series C of $100M was announced in May 2024.
Karius Founders and Leadership Team
Contact details for the Karius team: 1 of 1 has an email address on file.
Start 14-day free trial →Karius Funding Compared to Other Biotechnology Startups
Karius' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Karius in Biotechnology and Redwood City
Companies Similar to Karius
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Karius Funding FAQs
What does Karius do?
Karius is a biotech company that specializes in providing genomic information on infectious diseases through a non-invasive liquid biopsy. Their Karius Test aids healthcare providers in quickly determining the most effective treatment options. With the ability to analyze a patient's microbial makeup from just one blood sample, Karius aims to reduce the impact of infectious diseases on global health. The company's laboratory is certified by CLIA and accredited by CAP to conduct advanced clinical testing.
How much funding has Karius raised?
Karius has raised $265M across 2 rounds on record. The most recent is a Series C of $100M announced in May 2024.
When did Karius last raise funding?
Karius' most recent funding round on record is a Series C of $100M, announced in May 2024.
Who founded Karius?
FundedIQ lists Mickey Kertesz (Founder) at Karius.
Where is Karius headquartered?
Karius is based in Redwood City, California, United States.
How many employees does Karius have?
Karius is in the 101-250 employee band.
How does Karius' funding compare to other Biotechnology startups?
Karius' latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Karius Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Karius is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.